S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Peptide Tracker Updates Protocol Management Tools in Version 2.8.0

Los Angeles developers behind the Peptide Tracker app have launched version 2.8.0, introducing a foundational educational course and early access to upcoming social features. The update refines the user experience with improved navigation and expanded support for specific syringe measurements, aiming to streamline daily protocol management for its users.

Peptide Tracker Updates Protocol Management Tools in Version 2.8.0
Photo: Bio & News

The centerpiece of this release is "Peptide Basics," an educational module now accessible within the app’s Learn tab. Designed to provide a grounding in dosing and safety, the course serves as a direct resource for those navigating complex protocols. Alongside the new content, Founding Members receive priority access to "Connect," an upcoming social feature that allows them to reserve usernames and customize profile backgrounds.

Technical adjustments in this version focus on precision and usability. Users can now log doses using 3mL syringes, a change intended to accommodate specific protocol requirements more accurately. The Today tab has also undergone a visual overhaul to provide a clearer view of upcoming tasks. According to CTO JP Sio, the redesigned tab bar is a strategic move to simplify navigation as the platform continues to integrate new tools like inventory tracking and educational courses. Peptide Tracker remains a free, ad-free utility for protocol monitoring.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!